What is Mellitus?
Mellitus operates at the intersection of clinical research and diagnostic innovation, specifically focusing on the measurement of Glycated CD59 (GCD59). The company's core technology, derived from foundational research at Harvard Medical School, provides a novel biomarker for the screening, diagnosis, and monitoring of diabetes. By offering a more precise method for assessing glycemic control, Mellitus aims to improve patient outcomes through better risk stratification and the development of companion diagnostics for pharmaceutical applications. The firm's lead product candidate, an in vitro diagnostic assay for Gestational Diabetes Mellitus (GDM), represents a significant advancement in prenatal care and metabolic monitoring, supported by an exclusive patent portfolio.
How much funding has Mellitus raised?
Mellitus has raised a total of $3.1M across 2 funding rounds:
Debt
$992K
Debt
$2.1M
Debt (2016): $992K, investors not publicly disclosed
Debt (2017): $2.1M, investors not publicly disclosed
Key Investors in Mellitus
Undisclosed Institutional Investor
An undisclosed institutional partner providing debt financing to support the operational scaling of medical technology firms.
Undisclosed Private Equity Firm
A private equity entity focused on long-term capital appreciation within the life sciences and diagnostic sectors.
Undisclosed Strategic Partner
A strategic investor specializing in the commercialization of early-stage diagnostic assays and clinical research assets.
What's next for Mellitus?
With the recent influx of capital, Mellitus is expected to transition from its current research-heavy phase toward broader clinical validation and regulatory milestones. The strategic deployment of these funds will likely prioritize the scaling of its GDM diagnostic assay and the expansion of its clinical utility studies. As the company navigates the complexities of the diagnostic market, the focus will remain on establishing GCD59 as a standard-of-care biomarker. Future growth trajectories will likely involve deepening partnerships with pharmaceutical entities to utilize their assay as a companion diagnostic, thereby solidifying the company's role in the evolving ecosystem of precision medicine and chronic disease management.
See full Mellitus company page
